Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical excipients industry, indicating a positive outlook compared to the broader market [4]. Core Insights - The pharmaceutical excipients industry is undergoing an upgrade, with increasing specialization and scale as the regulatory framework and standards improve. The industry is expected to mature gradually [6][30]. - The implementation of the 2025 edition of the Chinese Pharmacopoeia, effective from October 1, 2025, introduces 52 new standards for pharmaceutical excipients, a 15.5% increase from the 2020 edition, totaling 387 standards. This is anticipated to enhance product quality and competitiveness in international markets, facilitating import substitution [6][28]. - The report highlights the strong performance of leading companies in the sector, such as Shanhe Pharmaceutical Excipients, which is positioned well to support pharmaceutical companies amid international changes. The company has shown steady growth and impressive export performance [6][30]. Summary by Sections 1. Importance of Pharmaceutical Excipients - Pharmaceutical excipients are essential components in drug production, influencing drug efficacy and manufacturing processes. They account for approximately 70% of the entire drug formulation [14][23]. 2. Development of the Pharmaceutical Excipients Industry - The industry is experiencing high-quality development, driven by improved regulatory environments and growing domestic demand. The market is expected to expand significantly, with a focus on high-end excipients and new formulations [30][31]. - The report notes that the domestic pharmaceutical excipients market is projected to reach approximately 48.28 billion yuan in 2024, with solid dosage form excipients accounting for about 33.8 billion yuan [32]. 3. Key Companies to Watch - Shanhe Pharmaceutical Excipients is highlighted as a leading player in the solid dosage excipients sector, with a robust product matrix and core technological advantages [6][30]. - Shandong Heda, a key player in the plant capsule market, is also recommended for investment due to its growth potential driven by the expanding health supplement market [2][6]. 4. Market Trends and Projections - The global health supplement market is expected to grow at a CAGR of approximately 5.4% from 2023 to 2028, potentially reaching nearly 1.4 trillion USD by 2028. The Chinese health supplement market is projected to reach 423.7 billion yuan by 2027 [6][30]. - The plant capsule market is anticipated to grow significantly, with global revenues expected to rise from approximately 1.535 billion USD in 2024 to 2.568 billion USD by 2031, driven by demand in both health supplements and pharmaceutical applications [6][30].

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Auxiliary, marks a significant event for the company, which he led for over 20 years, establishing it as a key player in the pharmaceutical excipients industry [4][5][6]. Company Overview - Shanhe Pharmaceutical Auxiliary announced the death of its controlling shareholder and chairman, Yin Zhenglong, on August 26, 2025, at the age of 60 [1]. - The company has updated its official website to a black-and-white page as a sign of mourning [2]. - Yin Zhenglong chaired the sixth board meeting on the morning of August 26, where two key proposals were approved, including the half-year report for 2025 [4]. Leadership and Vision - As the founder, Yin Zhenglong played a crucial role in the company's growth from a local pharmaceutical factory to a publicly listed entity on the Shenzhen Stock Exchange [5]. - He emphasized the importance of "technical marketing" and "pre-marketing," advocating for sales personnel to possess technical knowledge to provide solutions to clients [4]. - Yin aimed to replace imported pharmaceutical excipients with domestic products, which was a key development goal for the company [4]. Shareholding and Management Transition - Yin Zhenglong held 26.90% of the company's shares, making him the controlling shareholder [6]. - The company stated that the inheritance of his shares will be handled according to legal regulations, and the board's operations remain unaffected [6]. - Song Daocai, a board member and general manager, has been appointed as the interim chairman and legal representative until a new chairman is elected [6].